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Escalating health-care costs are a concern of every
country. This rising cost is a result of advanced tech-
nologies, aging population, increased utilization,
and is compounded with burdensome health-care
administrative costs. This concern triggered many
discussions to seek acceptable and effective ways to
contain cost. For example, recent discussion of US
Medicare Fund’s ability to cover all the retirees in
the future has caused many debates on Medicare
coverage. Many employers are exerting pressure on
providers to reduce health-care costs. Some employ-
ers, such as large automobile manufactures, claim
the cost of providing health care to their workers
has surpassed the cost of raw materials needed for
automobile production. From the health-care policy
perspective, how much should each nation spend on
health care and are these dollars being spent effec-
tively? What measures do we have to gauge the
value of health-care spending?
Out of the many components of the health-care
cost, prescription drug expenditures receive much
attention from the decision-makers. This is due to
the growth rates in expenditures for prescription
drugs in the past 10 years. Data from the United
States indicates there was a substantial annual
growth each year from 1994 to 1998 (from 10% to
17%) with a peak in 1999 (20%). In the last 4 years
the growth rate in prescription drug expenditures
has declined to 10.7% (2003) (Source: Centers for
Medicare and Medicaid Services (CMS). Ofﬁce of
Actuary). Many cost containment strategies have
been deployed to slow the growth rate of drug
expenditures, mainly working on the price and
demand variables.
The article by Tordoff et al. entitled “Managing
prices for hospital pharmaceuticals: a successful
strategy for New Zealand?” in the May/June 2005
issue of Value in Health is an example of these cost
cutting strategies [1]. In the United States, similar
negotiations are taking place daily by the buying
groups on behalf of hospitals and third-party insur-
ance companies. This strategy, for the most part,
employs the cost minimization technique to achieve
the cost savings without considering the compara-
tive effectiveness of the similar therapeutic agents.
Furthermore, it totally discards the hassle patients
must go through to obtain prescription medicines
after hospitalization. For example: Company A
offers a price discount for Drug A to a group of hos-
pitals, and fails to offer the same discount to the
third-party insurance companies for retail prescrip-
tions. This offer could potentially increase the mar-
ket shares of Drug A. To counter this move,
Company B offers a price concession for Drug B to
the third-party insurance companies for retail pre-
scriptions. Both medications are used for the same
disease and condition. If hospitals and the third-
party insurance companies have a preferred product
formulary requirement, Drug A will be the pre-
ferred choice for the hospitals and Drug B will be
the preferred choice for the third-party insurance
companies. To continue the drug therapy without
extra out-of-pocket expenditures, patients starting
treatment in the hospital and continuing as outpa-
tients are forced to switch from drug A to drug B.
The therapeutic goal will be achieved if both drugs
have a similar side-effect proﬁle and efﬁcacy. Nev-
ertheless, if these drugs are not equally efﬁcacious
or have different side-effect proﬁles, the cost-
effectiveness results will not be the same. In addi-
tion, if physicians insist on having Drug A for both
inpatient and outpatient care, in many instances,
they will be required to complete “prior authoriza-
tion” paperwork. In the meantime, patients may
not have any therapy at all. This formulary mis-
alignment has created unnecessary paperwork and
delay in therapy. From a societal perspective, has
any research been done to quantify the cost and
beneﬁt of the formulary misalignment?
The same situation applies to a second article in
the May/June 2005 issue of Value in Health by
Knight et al. [2]. These authors conclude that low
molecular weight heparin (LMWH) and vitamin K
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antagonist (VKA) combination is the most cost-
effective therapy for venous thromboembolism in
the hospital setting. These authors state that the
LMWH/VKA therapy decreases length of hospital
stay and has lower costs compared with other cur-
rent modalities. They also suggest that LMWH/
VKA might allow for outpatient treatment for this
condition. If the drug company decided to promote
this evidence-based practice (EBP), the drug com-
pany might offer a discount incentive for the
LMWH to hospitals, hoping to encourage adoption
of this EBP. The drug company’s lost revenues from
hospital sales could be recouped from increased
retail sales or an increase in retail price. What will
be the cost-effectiveness ratios of the discounted
price for the hospitals and higher price for the insur-
ance companies, respectively? How will this drug
company policy beneﬁt society? Furthermore, are
we shifting the cost from hospitals to the outpatient
setting?
Theoretically, the adoption of the LMWH/VKA
as a policy for the treatment of venous thromboem-
bolism could beneﬁt society. Nevertheless, there is
lack of evidence from a societal perspective to sup-
port this policy. Although many health-care policy
decisions are being made daily in all parts of the
health-care system, these policies/decisions are
implemented without an analysis of their impact in
other parts of the health-care delivery system. Many
policy decisions are made without in-depth analyses
from different perspectives, e.g., inpatient, outpa-
tient, patient, provider, societal, payers, etc. Even if
such analyses are performed, each care setting will
maximize its own gains and chose the most appro-
priate policy its own care setting rather than for
society as a whole. Despite the effort of formulary
guidelines, when they are implemented by health-
care decision-makers responsible for only part of
the health-care system, will they lead to an evi-
dence-based policy that has the greatest beneﬁt to
our society [3,4]?
Every health-care organization is unique with its
own budget constraints, prioritization of spending
and organizational culture. In addition, social,
political, and commercial factors often drive and
determine the use of evidence in policy-making [5].
Even though the policymakers use the existing sci-
entiﬁc evidence in the literature to set policy in good
faith, the societal consequences or results of these
acts are yet to be determined. When policymakers
claim they are practicing EBP based on studies in
their organizations, this may not be true because
this type of evidence does not necessarily lead to a
policy that will be of greatest beneﬁt to society.
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